Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Off-Label Use of Atypical Antipsychotics: An Update

Slide: 42 of 47

Trends in Off-Label Use of Atypical Antipsychotics

Since the FDA regulatory warning in 2005 about severe adverse events in the elderly (ages ≥65), the use of atypical antipsychotics for treating the elderly has declined. However, the statistical significance of the change is not known.

Off-label use of atypical antipsychotics is higher in long-term care settings than in the community.

No off-label use of the most recently approved atypical antipsychotics (asenapine, iloperidone, and paliperidone) has been reported in the literature.

Risperidone, quetiapine, and olanzapine are the most commonly prescribed atypical antipsychotics for off-label indications.